Saleem Shahzad
Critical Care Medicine · Brooklyn, NYNPI 1295043057
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.7% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. GSK accounts for 66.6% of it on its own, with 9 other manufacturers making up the rest.
Across 41 payments — averaging $68.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$575
- Novartis$127
- Actelion Pharmaceuticals US, Inc.$79
- Boston Scientific$45
- Genentech USA, Inc.$32
- plus $81 from 4 others
Across 7 payments — averaging $5002.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$35K
What the payments were for
- Food & beverage$2,71997%
- Education$933%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 20 | $1,874 |
| AstraZeneca | 7 | $575 |
| Novartis | 6 | $127 |
| Actelion Pharmaceuticals US, Inc. | 1 | $79 |
| Boston Scientific | 1 | $45 |
| Genentech USA, Inc. | 2 | $32 |
| Advanced Respiratory, Inc | 1 | $27 |
| AbbVie | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Aurinia Pharma U.S., Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,812 in reported general payments places this provider in the 85th percentile of 442 critical care medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 68 | $292,126 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 379 | $267,578 |
| OfevNintedanib Esylate | 12 | $159,137 |
| Fasenra PenBenralizumab | 21 | $113,542 |
| Breo ElliptaFluticasone/Vilanterol | 153 | $64,604 |
| Dupixent SyringeDupilumab | 15 | $51,320 |
| Spiriva RespimatTiotropium Bromide | 60 | $30,966 |
| SymbicortBudesonide/Formoterol Fumarate | 123 | $29,928 |
| Incruse ElliptaUmeclidinium Bromide | 57 | $23,136 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 99 | $16,542 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 504 | $15,438 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 25 | $15,042 |
| DuleraMometasone/Formoterol | 31 | $10,470 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 15 | $9,115 |
| Wixela InhubFluticasone Propion/Salmeterol | 49 | $8,614 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $1,874 | $364,433604 claims |
| AstraZenecaTezspire, Symbicort, Breztri Aerosphere | $575 | $337,096216 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 442 critical care medicine providers in New York.
Other critical care medicine in Brooklyn
- Joshua RosenbergBrooklyn$881K
- Mohammad ZamanBrooklyn$13K
- Yizhak KupferBrooklyn$8K
- Chetana PendkarBrooklyn$7K
- Steven BadinBrooklyn$5K
- Daniel BuchneaBrooklyn$4K
- Samir FahmyBrooklyn$4K
- Alibel BelloBrooklyn$4K
- Peter DicpinigaitisBronx$241K
- Roxana SulicaNew York$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.